Astra Enters Into $2 Billion-Plus Pact With UK Biotech Quell

AstraZeneca’s Japan Partner to Go Solo on Future Cancer Drugs

Your Sunday US Briefing: Shangri-la Handshake, Big Rate Decisions

Astra Drops Bowel Disease Drug Program After Delays

Catalent Cuts Annual Forecast More Than Expected, Delays Earnings Report Again

Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data

Concrete Giant Plans Formal Vote on US Listing: The London Rush